Epidermolysis bullosa simplex (EBS) is the most common form of epidermolysis bullosa, a rare dermatologic condition where patients (many of them children) have a genetic defect that compromises the structural integrity of their skin, making it particularly fragile and prone to blistering throughout their bodies. The disease can be severely debilitating and there are no treatment options currently available.
CCP-020 (diacerein topical ointment) is a new drug in development for the treatment of EBS and other forms of EB. It is believed to block an important inflammatory signaling pathway.
The U. S. Food and Drug Administration has granted Orphan Drug designation, Rare Pediatric Disease designation, and Fast Track designation to CCP-020 for treatment of EBS.
Explore Advocacy & Educational Resources